RT - European Journal of Gynaecological Oncology ID - 10.12892/ejgo2758.2016 T1 - Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors A1 - J.D. Santotoribio A1 - A. Garcia-de la Torre A1 - C. Cañavate-Solano A1 - F. Arce-Matute A1 - M.J. Sanchez-del Pino A1 - S. Perez-Ramos K1 - CEA; CA 15.3; CA 19.9; CA 125; Tumor markers; Mucinous ovarian cancer. YR - 2016 SP - 26 AB -

Purpose of investigation: To determine the accuracy of carcinoembryonic antigen (CEA), cancer antigen (CA) 15.3, CA 19.9, and CA125 for diagnosis of mucinous ovarian cancer (MOC). Materials and Methods: Samples were collected preoperatively from patients with mucinous ovarian tumor. The following variables were analysed: CEA, CA 15.3, CA 19.9, and CA 125. After surgery, histology and stage were determined according to FIGO-classification. Patients were classified into two groups according to the diagnosis of ovarian biopsy: NOT MOC and MOC. Results: The authors studied 94 patients with ages between 15 and 80 years (median = 43). Eightytwo patients were NOT MOC (68 mucinous ovarian cystadenomas and 14 mucinous borderline ovarian tumors) and 12 were MOC. All MOC patients were in FIGO Stages I or II. No statistically significant differences were found between MOC and NOT MOC patients according to CEA and CA 15.3 (p > 0.05). All MOC patients had abnormal serum CA 19.9 and/or CA 125 levels. Using CA 19.9 and CA 125, we performed a linear regression formula CA 19.9 + 125 = 0.00102 x CA 19.9 + 0.00057 x CA 125. AUCs values were 0.862 (p = 0.0002), 0.829 (p = 0.0021), and 0.911 (p = 0.0001) for CA 19.9, CA 125, and CA 19.9 + 125, respectively. CA 19.9 + 125 exhibited 95.1 % specificity and 66.7% sensitivity, increased by 16.7% sensitivity compared with using only CA 19.9 or CA 125. Conclusions: Preoperative CA 19.9 and CA 125 levels showed high diagnosis efficacy to predict whether a mucinous ovarian tumour is benign or malignant. Using both markers simultaneously increases the sensitivity for diagnosis of MOC.